NCT05363592 - A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 25, 2022

Primary Completion Date

July 5, 2022

Study Completion Date

July 25, 2022

Conditions

Healthy

Interventions

DRUG

CT-L01 12.5/500 mg

FDC tablet, 2 tablets at a time, oral administration

DRUG

Alogliptin Benzoate 12.5 mg

Alogliptin Benzoate 12.5 mg 2 tablets, at a time, oral administration

DRUG

Metformin HCl XR 500 mg

Metformin HCl XR 500 mg 2 tablets, at a time, oral administration

Trial Locations (1)

Chungnam National University Hospital, Daejeon